London’s Alternative Investment Market may not generally command the attention of its bigger sibling, the main market of the London Stock Exchange, but all eyes will be on Aim next week. Three companies are looking to delist from the junior market and their plans are being put to investors in a series of shareholder votes.
Significantly, two involve a pair of Britain’s leading biotechnology players. Both C4X Discovery and Redx Pharma believe that they can raise more money as private companies.
Their decisions to quit Aim would be notable enough in themselves, but they have shone a spotlight on structural weaknesses in the small-cap market and have rung alarm bells about a broader malaise. Suddenly, concerns have switched from the recent flight of big listed
